Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prostate Brachytherapy $5,381 Payment Rate Inadequate – Stakeholders

This article was originally published in The Gray Sheet

Executive Summary

CMS will need to determine whether the two isotopes used in prostate brachytherapy are cost equivalent before the agency publishes its 2003 hospital outpatient prospective payment system (OPPS) final rule on Nov. 1
Advertisement

Related Content

OPPS Rule Establishes Separate Palladium, Iodine G Codes For Brachytherapy
OPPS Rule Establishes Separate Palladium, Iodine G Codes For Brachytherapy
Prostate Brachytherapy Sources Vary By $5,570, Violate 2X Rule – CAB Data
Prostate Brachytherapy Sources Vary By $5,570, Violate 2X Rule – CAB Data
OPPS 2003 Proposed Rule Contains Payment Cuts For 80% Of Devices – Scully
Brachytherapy Seed Manufacturers Rally For Discrete OPPS Payment Codes
Brachytherapy Seed Manufacturers Rally For Discrete OPPS Payment Codes
Advertisement
UsernamePublicRestriction

Register

MT017034

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel